Member Info for volcano

next stop 43p

Midatech chief confident OpsiSporin will reach market Share 11:16 22 Apr 2016 Midatech Pharma PLC (LON:MTPH, NASDAQ:MTP) said a study it is conducting on a treatment for an inflammatory eye disorder delivered some encouraging results. Its preclinical work was designed to assess the efficacy of drug candidate OpsiSporin in treating uveitis. Jim Phillips, chief executive, tells Proactive Investors the treatment could be “one of the first really localised effective treatments for this condition”. He says that the product will take two to three years of clinical studies with the product likely to be marketed by 2020-2021 adding that “because it is using an active ingredient that we know works and that the data we’ve now produced is good, it makes us increasingly confident that it will reach market”.

Ferrexpo Plc (FXPO) Receives “Sell” Rating from Investec April 20th, 2016 - By John Bondi - 0 comments Ferrexpo Plc logoFerrexpo Plc (LON:FXPO)‘s stock had its “sell” rating reissued by Investec in a report issued on Wednesday, Marketbeat.com reports. They currently have a GBX 24 ($0.34) price objective on the iron ore producer’s stock. Investec’s price target would suggest a potential downside of 26.72% from the stock’s current price. Shares of Ferrexpo Plc (LON:FXPO) traded up 8.3969% during mid-day trading on Wednesday, reaching GBX 35.5000. The company’s stock had a trading volume of 1,047,491 shares. The company’s market cap is GBX 207.84 million. Ferrexpo Plc has a 52-week low of GBX 12.50 and a 52-week high of GBX 83.00. The company has a 50-day moving average price of GBX 31.04 and a 200 day moving average price of GBX 27.22.

as the yanks say it - wow

excellent company to trade in

read the brokers rating

they know jack ,,,,

looks like another good day ,up to 34p now

Average volume 379.14k Shares outstanding 190.13m Free float 32.93m P/E (TTM) 5.93 Market cap 44.83m GBP EPS (TTM) 0.0398 GBP

MAIL ON SUNDAY The equipment hire industry has gained an unfortunate reputation for disappointment. HSS Hire has lost 65 per cent of its market value since floating in February 2015. Sadly, Speedy Hire shares have also slumped since they were recommended by Midas that same month. Even Ashtead, their much larger peer, has been affected by concerns about the outlook for the sector. Lavendon Group has been dragged down in their wake. Trading at more than 200p last June, the stock is now 133¼p. But the company is different from its listed rivals and the shares deserve to move higher. Lavendon specialises in powered access equipment – machines that enable workers to operate safely and productively at height. The company’s equipment is generally associated with helping contractors constructing huge buildings such as airports, logistics warehouses and shopping malls. But its kit is also used to install and maintain mobile phone masts and wind turbines, clean high buildings, film events including the Abu Dhabi Grand Prix, and even renovate old structures and buildings such as Clifton Suspension Bridge in Bristol, Cologne cathedral and the Louvre in Paris. Lavendon’s results for 2015 were above expectations and a first-quarter trading update this week should strike a confident note. Brokers forecast a 4 per cent rise in 2016 pre-tax profits to £40.1 million, with stronger growth in 2017. The group is paying a 5.4p dividend for 2015, expected to rise to about 5.8p this year. Midas verdict: Lavendon is suffering by association with the wider equipment rental sector, but it is more specialised than its peers and has a six-year record of profit and dividend growth. At 133¼p, the shares are worth tucking away. Read more: http://www.thisismoney.co.uk/money/investing/article-3532613/SUNDAY-NEWSPAPER-SHARE-TIPS-Lavendon-Group-Burberry.html#ixzz45nlXW9Qh Follow us: @MailOnline on Twitter | DailyMail on Facebook

there she goes 122p

nearly doubled in two month

Panmure Gordon Retained Midatech Pharma Plc (LON:MTPH) As ‘Buy’ By Warren Smith / in UK Broker Ratings / on Tuesday, 12 Apr 2016 09:40 AM / 0 Comments On Sunday analysts at Panmure Gordon retained Midatech Pharma Plc’s (LON:MTPH) shares as ‘Buy’ in a research note issued to investors. Following Panmure Gordon’s latest price target of 476 on the business this highlights that the broker now believes there is an increase of 180% from Midatech Pharma Plc’s current share price of 170. The number of shares Midatech Pharma Plc currently has in issue is 27,810,000, which have a value of 170 per share calculating Midatech Pharma Plc’s market capitalisation to 47.28M GBP. Midatech Pharma Plc Twelve Month Chart For Midatech Pharma Plc LON:MTPH Over the last 52 weeks Midatech Pharma Plc’s stock price has increased by 0% from 0.00 to 170. Shares in Midatech Pharma Plc have risen as high as 320 in the past 52 weeks whilst the lowest price in the last 52 weeks has been 133. The business’s 50 day moving average is 160.66 and its 200 day moving average is 210.46. Midatech Pharma Plc is a United Kingdom-based nanomedicine company. The Company is focused on the development and commercialization of various therapeutic products for diseases, which include diabetes, certain cancers, such as liver, ovarian and brain (glioblastoma), and certain neurological/ophthalmologic conditions. Its product candidates, which are in clinical and pre-clinical development, are Transbuccal Insulin, glucagon-like-peptide (GLP-1), GLP-1/Insulin Combination, Q-Exenatide and Q-Octreotide. It is also developing oncology products for the treatment of brain cancer (glioblastoma), ovarian cancer, liver cancer and pancreatic cancer. Its pipeline of product candidates is based on its drug conjugate and sustained release delivery platforms. The Company also offers Zuplenz for the prevention of chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting.

Panmure Gordon Retained Midatech Pharma Plc (LON:MTPH) As ‘Buy’ By Warren Smith / in UK Broker Ratings / on Tuesday, 12 Apr 2016 09:40 AM / 0 Comments On Sunday analysts at Panmure Gordon retained Midatech Pharma Plc’s (LON:MTPH) shares as ‘Buy’ in a research note issued to investors. Following Panmure Gordon’s latest price target of 476 on the business this highlights that the broker now believes there is an increase of 180% from Midatech Pharma Plc’s current share price of 170. The number of shares Midatech Pharma Plc currently has in issue is 27,810,000, which have a value of 170 per share calculating Midatech Pharma Plc’s market capitalisation to 47.28M GBP. Midatech Pharma Plc Twelve Month Chart For Midatech Pharma Plc LON:MTPH Over the last 52 weeks Midatech Pharma Plc’s stock price has increased by 0% from 0.00 to 170. Shares in Midatech Pharma Plc have risen as high as 320 in the past 52 weeks whilst the lowest price in the last 52 weeks has been 133. The business’s 50 day moving average is 160.66 and its 200 day moving average is 210.46. Midatech Pharma Plc is a United Kingdom-based nanomedicine company. The Company is focused on the development and commercialization of various therapeutic products for diseases, which include diabetes, certain cancers, such as liver, ovarian and brain (glioblastoma), and certain neurological/ophthalmologic conditions. Its product candidates, which are in clinical and pre-clinical development, are Transbuccal Insulin, glucagon-like-peptide (GLP-1), GLP-1/Insulin Combination, Q-Exenatide and Q-Octreotide. It is also developing oncology products for the treatment of brain cancer (glioblastoma), ovarian cancer, liver cancer and pancreatic cancer. Its pipeline of product candidates is based on its drug conjugate and sustained release delivery platforms. The Company also offers Zuplenz for the prevention of chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting.

The stock of Highland Gold Mining Ltd (LON:HGM) hit a new 52-week high and has GBX 207.34 target or 185.00% above today’s GBX 72.75 share price. The 9 months bullish chart indicates low risk for the GBX 235.46 million company. The 1-year high was reported on Apr, 12 by Barchart.com. If the GBX 207.34 price target is reached, the company will be worth GBX 435.60M more. The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 5.43% or GBX 3.75 on April 11, hitting GBX 72.75. About 995,615 shares traded hands or 72.89% up from the average. Highland Gold Mining Ltd (LON:HGM) has risen 46.97% since September 10, 2015 and is uptrending. It has outperformed by 42.31% the S&P500.

Highland Gold Mining Ltd’s Stock Is Buy After Reaching 52-Week High

Ferrexpo Plc 189.9% Potential Upside Indicated by Cantor Fitzgerald

Ferrexpo PLC (LON:FXPO) Rating Ferrexpo PLC (LON:FXPO) stock had its Buy Rating restate by analysts at Deutsche Bank in an analyst note published on 31 March

i am not from 40p to over £4 ,nice .

Directors Deals for Dji Holdings (DJI) Trade Date Action Notifier Price Currency Amount Holding 20-Oct-15 Sell Trade Notifier Information for DJI Holdings Rodney St. Auburn Davis 43.9 GBX 25,000 2768702 13-Oct-15 Sell Trade Notifier Information for DJI Holdings Rodney St. Auburn Davis 43.67 GBX 17,000 2768702 09-Oct-15 Sell Trade Notifier Information for DJI Holdings Rodney St. Auburn Davis 46.05 GBX 3,000 2768702 07-Oct-15 Sell Trade Notifier Information for DJI Holdings Rodney St. Auburn Davis 46.61 GBX 55,000 0 06-Oct-15 Sell Trade Notifier Information for DJI Holdings Rodney St. Auburn Davis 46.75 GBX 5,000 0 30-Sep-15 Sell Trade Notifier Information for DJI Holdings Rodney St. Auburn Davis 48.92 GBX 150,000 0 21-Jul-14 Transfer From Trade Notifier Information for DJI Holdings Simon Erroll Prior-Palmer 0 80,000 3344504